RCUS
Price
$12.19
Change
+$0.63 (+5.45%)
Updated
Sep 5 closing price
Capitalization
1.3B
66 days until earnings call
TLPPF
Price
$9.04
Change
-$0.18 (-1.95%)
Updated
Sep 5 closing price
Capitalization
3.02B
Interact to see
Advertisement

RCUS vs TLPPF

Header iconRCUS vs TLPPF Comparison
Open Charts RCUS vs TLPPFBanner chart's image
Arcus Biosciences
Price$12.19
Change+$0.63 (+5.45%)
Volume$1.1M
Capitalization1.3B
Telix Pharmaceutical
Price$9.04
Change-$0.18 (-1.95%)
Volume$569
Capitalization3.02B
RCUS vs TLPPF Comparison Chart in %
Loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLPPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCUS vs. TLPPF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a Buy and TLPPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (RCUS: $12.19 vs. TLPPF: $9.04)
Brand notoriety: RCUS and TLPPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 146% vs. TLPPF: 7%
Market capitalization -- RCUS: $1.3B vs. TLPPF: $3.02B
RCUS [@Biotechnology] is valued at $1.3B. TLPPF’s [@Biotechnology] market capitalization is $3.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileTLPPF’s FA Score has 1 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • TLPPF’s FA Score: 1 green, 4 red.
According to our system of comparison, RCUS is a better buy in the long-term than TLPPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 5 TA indicator(s) are bullish while TLPPF’s TA Score has 4 bullish TA indicator(s).

  • RCUS’s TA Score: 5 bullish, 4 bearish.
  • TLPPF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than TLPPF.

Price Growth

RCUS (@Biotechnology) experienced а +15.11% price change this week, while TLPPF (@Biotechnology) price change was -8.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

RCUS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLPPF($3.02B) has a higher market cap than RCUS($1.3B). RCUS YTD gains are higher at: -18.133 vs. TLPPF (-39.633). TLPPF has higher annual earnings (EBITDA): 92.5M vs. RCUS (-282M). RCUS has more cash in the bank: 911M vs. TLPPF (710M). RCUS has less debt than TLPPF: RCUS (109M) vs TLPPF (581M). TLPPF has higher revenues than RCUS: TLPPF (783M) vs RCUS (262M).
RCUSTLPPFRCUS / TLPPF
Capitalization1.3B3.02B43%
EBITDA-282M92.5M-305%
Gain YTD-18.133-39.63346%
P/E RatioN/A387.72-
Revenue262M783M33%
Total Cash911M710M128%
Total Debt109M581M19%
FUNDAMENTALS RATINGS
RCUS vs TLPPF: Fundamental Ratings
RCUS
TLPPF
OUTLOOK RATING
1..100
1556
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
10055
SMR RATING
1..100
9868
PRICE GROWTH RATING
1..100
4694
P/E GROWTH RATING
1..100
985
SEASONALITY SCORE
1..100
5014

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (50) in the Pharmaceuticals Major industry is somewhat better than the same rating for TLPPF (93) in the null industry. This means that RCUS’s stock grew somewhat faster than TLPPF’s over the last 12 months.

TLPPF's Profit vs Risk Rating (55) in the null industry is somewhat better than the same rating for RCUS (100) in the Pharmaceuticals Major industry. This means that TLPPF’s stock grew somewhat faster than RCUS’s over the last 12 months.

TLPPF's SMR Rating (68) in the null industry is in the same range as RCUS (98) in the Pharmaceuticals Major industry. This means that TLPPF’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's Price Growth Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for TLPPF (94) in the null industry. This means that RCUS’s stock grew somewhat faster than TLPPF’s over the last 12 months.

TLPPF's P/E Growth Rating (5) in the null industry is significantly better than the same rating for RCUS (98) in the Pharmaceuticals Major industry. This means that TLPPF’s stock grew significantly faster than RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSTLPPF
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
68%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
68%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 11 days ago
75%
Declines
ODDS (%)
Bearish Trend 30 days ago
82%
Bearish Trend 5 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLPPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEGOX40.030.83
+2.12%
First Eagle Gold C
EIMGX33.070.05
+0.15%
Eaton Vance Tx-Mgd Small-Cap I
BRWBX26.48N/A
N/A
MFS Blended Research Growth Eq B
RPEBX69.33N/A
N/A
American Funds New Perspective R2E
JSVZX25.53N/A
N/A
JPMorgan Small Cap Value R2

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+5.45%
XNCR - RCUS
50%
Loosely correlated
+2.15%
CRNX - RCUS
50%
Loosely correlated
+3.97%
MNMD - RCUS
50%
Loosely correlated
-0.11%
TRDA - RCUS
49%
Loosely correlated
+1.34%
IDYA - RCUS
48%
Loosely correlated
+5.15%
More

TLPPF and

Correlation & Price change

A.I.dvisor tells us that TLPPF and BDTX have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLPPF and BDTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLPPF
1D Price
Change %
TLPPF100%
-1.95%
BDTX - TLPPF
22%
Poorly correlated
+2.44%
ITOS - TLPPF
21%
Poorly correlated
N/A
RCUS - TLPPF
21%
Poorly correlated
+5.45%
ORMP - TLPPF
21%
Poorly correlated
+0.45%
ABOS - TLPPF
20%
Poorly correlated
+4.35%
More